• FAQS
  • ABOUT
  • LOG IN
  • SIGN UP

JANSSEN Overview

Upcoming Projects (JANSSEN) Image
  • Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (JANSSEN) Image
  • Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (JANSSEN) Image
  • Genmab Achieves USD 30 Million Milestone in DARZALEX (daratumumab) Collaboration with Janssen
    Tickers: JANSSEN, GE9.F
    Occurred on: May 30, 2016
  • FDA Expands Indication of INVOKAMET (canagliflozin/metformin HCl) to Include First-Line Treatment of Adults with Type 2 Diabetes
    Ticker: JANSSEN
    Occurred on: May 24, 2016
  • New Phase 3 Study Findings Show STELARA Maintained Clinical Remission After One Year Of Treatment In Patients With Moderate To Severe Crohn's Disease
    Ticker: JANSSEN
    Occurred on: May 23, 2016
Strategic Initiatives (JANSSEN) Image
  • Depomed Announces Closing of Acquisition of U.S. Rights to NUCYNTA (tapentadol), NUCYNTA ER (tapentadol) extended release tablets and NUCYNTA (tapentadol) oral solution from Janssen Pharmaceuticals, Inc. for $1.05 billion
    Tickers: DEPO, Janssen
    Announcement Date: Apr 02, 2015
About Us
  • About
  • Pricing
  • Compliance
  • Terms of Use
  • Privacy Policy
Media Center
  • Jobs
Connect with Us
  • facebook Facebook
  • facebook Twitter
  • facebook LinkedIn
  • facebook Email Us
© 2025 Slingshot Insights. All rights reserved.